Alumis Inc.
ALMS
株式のランク
#10179
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
株価
$6.41
最終同期: 2026-10-19
時価総額
$830.25M
変化（1日）
4.81%
変化（1年）
182.57%
国
US
取引 Alumis Inc. (ALMS)
カテゴリー
Healthcare
Alumis Inc.（ALMS）の利益
Mar 2025 時点の利益 TTM: $-268.52M
Alumis Inc. の最新の財務報告によると、同社の現在の利益は $-268.52M です。2023 年には $-381.64M の利益を上げ、これは 2022 年の利益 $-64.77M と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Alumis Inc. の利益の推移（2021 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $-268.52M | 8.17% |
| 2024 | $-248.23M | -34.96% |
| 2023 | $-381.64M | 489.21% |
| 2022 | $-64.77M | 54.81% |
| 2021 | $-41.84M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $5.27B | -2,064.46% |
US
|
|
| $-3.09B | 1,049.65% |
US
|
|
| $-4.02B | 1,395.70% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -826.45% |
NL
|
